Synergistic antitumor effect of oroxylin A and donafenib in hepatocellular carcinoma through tumor protein p53 signaling pathway activation

Figure 7 Knockdown of murine double minute 2 affects oroxylin A/donafenib-induced dysregulation of tumor protein p53 signaling-related proteins. A and B: The protein expression of tumor protein p53, cell division cycle 7, cyclin-dependent kinase 9, murine double minute 2 (MDM2), phosphorylated MDM2, MDM4, phosphorylated MDM4, B-rapidly accelerated fibrosarcoma proto-oncogene serine/threonine kinase, and vascular endothelial growth factor receptor was detected using western blot analysis after the genetic silencing of cyclin-dependent kinase 9 and exposure to oroxylin A (A) or donafenib (B) for 24 hours in MHCC-97H and PLC-PRF-5 cell lines. OA: Oroxylin A; DF: Donafenib; MDM2: Murine double minute 2; BRAF: B-rapidly accelerated fibrosarcoma proto-oncogene serine/threonine kinase; CDC7: Cell division cycle 7; CDK9: Cyclin-dependent kinase 9; MDM4: Murine double minute 4; p-MDM4: Phosphorylated murine double minute 4; p-MDM2: Phosphorylated murine double minute 2; TP53: Tumor protein p53; VEGFR: Vascular endothelial growth factor receptor.